Orthofix Medical Inc. (NASDAQ:OFIX) Given Consensus Recommendation of “Hold” by Analysts

Orthofix Medical Inc. (NASDAQ:OFIX) has been assigned an average recommendation of “Hold” from the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $14.75.

OFIX has been the topic of several recent analyst reports. Weiss Ratings lowered Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. TD Cowen reaffirmed a “hold” rating on shares of Orthofix Medical in a research note on Thursday, May 21st. Wall Street Zen cut Orthofix Medical from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Stifel Nicolaus lowered their target price on Orthofix Medical from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 22nd. Finally, Canaccord Genuity Group dropped their target price on shares of Orthofix Medical from $18.00 to $13.00 and set a “buy” rating for the company in a report on Monday, August 10th.

Insider Buying and Selling

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,670 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.38, for a total transaction of $34,424.60. Following the sale, the insider directly owned 66,330 shares of the company’s stock, valued at $622,175.40. The trade was a 5.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Orthofix Medical

A number of hedge funds have recently modified their holdings of OFIX. R Squared Ltd increased its holdings in Orthofix Medical by 7.2% in the first quarter. R Squared Ltd now owns 13,518 shares of the medical device company’s stock valued at $155,000 after purchasing an additional 904 shares during the period. Gabelli Funds LLC raised its position in Orthofix Medical by 0.4% during the 4th quarter. Gabelli Funds LLC now owns 235,303 shares of the medical device company’s stock worth $3,567,000 after purchasing an additional 1,000 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in Orthofix Medical by 1.5% during the 3rd quarter. Raymond James Financial Inc. now owns 66,812 shares of the medical device company’s stock worth $978,000 after buying an additional 1,000 shares during the period. Amundi grew its position in shares of Orthofix Medical by 2.7% in the 4th quarter. Amundi now owns 41,527 shares of the medical device company’s stock valued at $630,000 after buying an additional 1,086 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Orthofix Medical by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock valued at $335,000 after buying an additional 1,213 shares during the last quarter. Institutional investors and hedge funds own 89.76% of the company’s stock.

Orthofix Medical Trading Up 0.7%

Shares of OFIX stock opened at $9.70 on Friday. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 0.55. The stock has a market cap of $395.08 million, a P/E ratio of -6.30 and a beta of 0.68. The stock has a 50 day simple moving average of $10.66 and a 200 day simple moving average of $11.37. Orthofix Medical has a 1 year low of $8.85 and a 1 year high of $16.99.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings data on Wednesday, August 5th. The medical device company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.02. Orthofix Medical had a negative net margin of 7.41% and a negative return on equity of 14.05%. The firm had revenue of $210.93 million for the quarter, compared to the consensus estimate of $209.28 million. On average, research analysts predict that Orthofix Medical will post -1.29 earnings per share for the current fiscal year.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.